ALK and non-small cell lung carcinoma: Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur in 3–7% of NSCLC cases and confer marked sensitivity to ALK tyrosine kinase inhibitors (TKIs) (3, 4).